.png){kind=icon}
.png){kind=icon}
Return
Development of microRNA-based therapeutics for central nervous system diseases
.png){kind=icon}
PRE
AI
S
C
F
G
DOI：10.1016/j.ejphar.2023.175956.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
MicroRNA (miRNA)-mediated gene silencing is a method of RNA interference in which a miRNA binds to messenger RNA sequences and regulates target gene expression. MiRNA-based therapeutics have shown promise in treating a variety of central nervous system diseases, as verified by results from diverse preclinical model organisms. Over the last decade, several miRNA-based therapeutics have entered clinical trials for various kinds of diseases, such as tumors, infections, and inherited diseases. However, such clinical trials for central nervous system diseases are scarce, and many central nervous system diseases, including hemorrhagic stroke, ischemic stroke, traumatic brain injury, intractable epilepsy, and Alzheimer's disease, lack effective treatment. Consid-ering its effectiveness for central nervous system diseases in preclinical experiments, microRNA-based inter-vention may serve as a promising treatment for these kinds of diseases. This paper reviews basic principles and recent progress of miRNA-based therapeutics and summarizes general procedures to develop such therapeutics for treating central nervous system diseases. Then, the current obstacles in drug development are discussed. This review also provides a new perspective on possible solutions to these obstacles in the future.
Keywords:
microRNA
Therapeutics
Drug
Central nervous system
Modification
Delivery
Journal
IF:
4.7
Papers:
2.3W
Citations:
4.0W
Organization
Cited Papers